• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Glenmark Pharma gets ANDA tentative approval for Dabigatran Etexilate Capsules

expresspharmaDecember 22, 2020

Tag: Glenmark , Dabigatran Etexilate Capsules , ANDA , Pradaxa Capsules , FDA

Glenmark Pharmaceuticals has received tentative approval by the United States Food & Drug Administration (US FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg, the generic version of Pradaxa Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals.

According to IQVIA sales data for the 12 month period ending October 2020, the Pradaxa Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 million.

Glenmark’s current portfolio consists of 166 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

Previous:Takeda to divest select assets in China to Hasten Biopharmaceutic for $322 mn

Next:Sosei Heptares and GSK sign collaboration and license pact targeting GI immune disorders

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Glenmark Pharma gets ANDA tentative approval for Dabigatran Etexilate Capsules | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Rutin NF11 (USP 32 Standard)

Rutin NF11 (USP 32 Standard)
Certified GMP Standard10~80% Ginsenosides Panax Ginseng Extract

Certified GMP Standard10~80% Ginsenosides Panax Ginseng Extract

Self-adhesive bandage

Self-adhesive bandage
The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING

The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING
Deoxycyline (FDA)

Deoxycyline (FDA)
Tubular bandage

Tubular bandage
RJ - sandals frame

RJ - sandals frame
Deltamine (FDA)

Deltamine (FDA)
Non-standard customized freeze dryer

Non-standard customized freeze dryer
Anastrozole usp standard pharma grade made in China

Anastrozole usp standard pharma grade made in China

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service